


## PHARMACEUTICAL 2018



## CNBX Pharmaceuticals Inc. Rank 191 of 349





## PHARMACEUTICAL 2018



## CNBX Pharmaceuticals Inc. Rank 191 of 349

The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 268% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is -213%, being 65% points above the market average of -278%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 3,517             |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 699               |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 0                 |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 287               |
| Other Liabilities                           | 0                 |
| Other Net Income                            | -74               |
| Property and Equipment                      | 120               |
| Research and Development                    | 247               |
| Revenues                                    | 0                 |
| Selling, General and Administrative Expense | 1,325             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 3,638             |
| Liabilities              | 699               |
| Expenses                 | 1,860             |
| Stockholders Equity      | 2,939             |
| Net Income               | -1,934            |
| Comprehensive Net Income | -1,934            |
| Economic Capital Ratio   | -213%             |